CHICAGO, July 14, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 133,000 shares of its common stock in the open market at an average price of approximately $0.298 per share. The Company has now repurchased a total of approximately 4,488,000 shares for approximately $941,000 under its previously announced share repurchase program of up to $5 million.

globenewswire.com - 2026-07-14 14:40:00

CHICAGO, July 13, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 215,000 shares of its common stock in the open market at an average price of approximately $0.325 per share. The Company has now repurchased a total of 4,355,000 shares for approximately $901,000 under its previously announced share repurchase program of up to $5 million.

globenewswire.com - 2026-07-13 15:00:00

Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in Greece Five-year agreement expected to contribute to revenue and cash-flow visibility As a prescription medicine, DIABIT-IS X is expected to be accessible to patients through Greece's national health insurance system, broadening its potential reach DIABIT-IS X is a generic alternative to Merck's Januvia®, which with Janumet® generated approximately $4.5 billion in combined global sales in 2022 Positions Cosmos Health in the large and established European sitagliptin market CHICAGO, July 13, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has entered into an agreement for the commercialization of its type-2 diabetes medication DIABIT-IS X (sitagliptin phosphate) in the Greek market, through a distribution and promotion partnership with Libytec Pharmaceutical S.A. ("Libytec").

globenewswire.com - 2026-07-13 13:00:00

Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in Greece Five-year agreement expected to contribute to revenue and cash-flow visibility As a prescription medicine, DIABIT-IS X is expected to be accessible to patients through Greece's national health insurance system, broadening its potential reach DIABIT-IS X is a generic alternative to Merck's Januvia, which with Janumet generated approximately $4.

globenewswire.com - 2026-07-13 13:00:00

Subscription model already launched with NOOR Collagen in the United States Early data shows a repeat purchase rate above 60% at high margins in excess of 50% Model is designed to drive stronger loyalty, greater lifetime value, and more predictable cash-flow visibility Company plans to extend the subscription model to additional Cosmos Health products globally, with further initiatives already underway CHICAGO, July 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has launched a subscription-based purchasing model for its proprietary consumer health brands. The model is currently live with NOOR Collagen in the United States, with encouraging early results that include a repeat purchase rate above 60% and margins in excess of 50%.

globenewswire.com - 2026-07-10 10:55:00

Subscription model already launched with NOOR Collagen in the United States Early data shows a repeat purchase rate above 60% at high margins in excess of 50% Model is designed to drive stronger loyalty, greater lifetime value, and more predictable cash-flow visibility Company plans to extend the subscription model to additional Cosmos Health products globally, with further initiatives already underway CHICAGO, July 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc.

globenewswire.com - 2026-07-10 10:55:00

CHICAGO, July 09, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 80,000 shares of its common stock in the open market at an average price of approximately $0.2503 per share. The Company has now repurchased a total of 4,140,000 shares for approximately $831,000 under its previously announced share repurchase program of up to $5 million.

globenewswire.com - 2026-07-09 15:45:00

CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 190,000 shares of its common stock in the open market at an average price of approximately $0.2805 per share. The Company has now repurchased a total of 4,060,000 shares for approximately $811,000 under its previously announced share repurchase program of up to $5 million.

globenewswire.com - 2026-07-08 15:40:00

CHICAGO, July 07, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 230,000 shares of its common stock in the open market at an average price of approximately $0.2539 per share. The Company has now repurchased a total of 3,870,000 shares for approximately $758,000 under its previously announced share repurchase program of up to $5 million.

globenewswire.com - 2026-07-07 14:27:00

CHICAGO, July 07, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 230,000 shares of its common stock in the open market at an average price of approximately $0.

globenewswire.com - 2026-07-07 14:27:00

Record Q2 2026 revenue of approximately $19.4 million, up approximately 31.5% year-over-year from $14.75 million in Q2 2025 Record first-half 2026 revenue of approximately $37.3 million, up approximately 31% from $28.46 million in H1 2025 3,640,000 shares repurchased as of July 6, 2026 for approximately $700,000 under the Company's $5 million buyback program, with open market purchases ongoing CHICAGO, July 07, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided a business update on its second quarter and first-half revenue performance and share repurchase activity. Record Q2 and H1 2026 Revenue: Based on preliminary results, the Company expects to report second-quarter 2026 revenue of approximately $19.4 million, up approximately 31.5% from $14.75 million in Q2 2025, and first-half revenue of approximately $37.3 million, up approximately 31% from $28.46 million in H1 2025 — both the highest in the Company's history.

globenewswire.com - 2026-07-07 09:29:00

CHICAGO, July 06, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 220,000 shares of its common stock in the open market at an average price of approximately $0.2229 per share, continuing the buyback activity carried out under its ongoing repurchase program. The Company has now repurchased a total of 3,640,000 shares for approximately $700,000 under its previously announced share repurchase program of up to $5 million.

globenewswire.com - 2026-07-06 14:30:00

CHICAGO, July 02, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 770,000 shares of its common stock in the open market at an average price of approximately $0.1956 per share, extending the buyback activity it began this week. The Company has now repurchased a total of 3,420,000 shares for approximately $650,000 under its previously announced share repurchase program of up to $5 million.

globenewswire.com - 2026-07-02 14:10:00

CHICAGO, July 01, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased 2,650,000 shares of its common stock for a total of $500,000 in the open market, at an average price of approximately $0.

globenewswire.com - 2026-07-01 11:05:00

CHICAGO, July 01, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased 2,650,000 shares of its common stock for a total of $500,000 in the open market, at an average price of approximately $0.1887 per share. The repurchases were made pursuant to the share repurchase program of up to $5 million announced on June 30, 2026, under which the Company may repurchase shares from time to time in the open market, through privately negotiated transactions, or through other permitted means in accordance with SEC Rules 10b5-1 and 10b-18 and other applicable restrictions.

globenewswire.com - 2026-07-01 11:05:00

CHICAGO, June 30, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its Board of Directors has authorized a share repurchase program of up to $5 million of the Company's common stock. Cosmos Health may repurchase shares from time to time in the open market, through privately negotiated transactions, or through other permitted means in accordance with SEC Rules 10b5-1 and 10b-18 and other applicable restrictions.

globenewswire.com - 2026-06-30 11:55:00

CHICAGO, June 26, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced a distribution agreement with International Medical Company ("IMC") to expand its presence in the State of Qatar for its proprietary Sky Premium Life line of nutraceuticals and food supplements.

globenewswire.com - 2026-06-26 12:30:00

Cosmos Health signs distribution agreement with IMC, owner of Qatar's largest pharmacy chain. Secures purchase order of 31,000 Sky Premium Life units.

globenewswire.com - 2026-06-26 12:30:00

Building on Its Recent Acquisition of the CCX0722 Intellectual Property, Cosmos Health Owns the Technology Outright and Is Now Pursuing Patent Protection Across Four Major Healthcare Markets Within the $190+ Billion Global Weight Management Category Advances international patent application WO2025108566A1, titled "Hydrogel for Body Weight Management," into the U.S., Europe, Australia, and Canada — four of the world's largest healthcare markets Builds on Cana Laboratories' acquisition of the patent application from Cloudpharm, bringing full ownership of the underlying intellectual property into the Cosmos Health portfolio, with no licensing fees, royalty-sharing, or third-party IP dependency Three-plus years of disciplined R&D execution — from concept in 2022 through pilot production, scale-up, and final-stage development Positioned within the rapidly growing global weight management market, estimated at $190.6 billion in 2025 and projected to reach $562.2 billion by 2033 at a 14.2% CAGR, as obesity becomes one of healthcare's most capital-intensive categories Management believes CCX0722 represents one of Cosmos Health's most strategically significant proprietary assets, with multiple potential paths to value creation — including licensing, co-development, and strategic partnerships CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. (“Cana”), has advanced international patent application WO2025108566A1 into the European regional phase and the national phases in the United States, Australia, and Canada.

globenewswire.com - 2026-06-25 15:31:00

CHICAGO, June 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided an update on the growing momentum of C-Sept™ PRO, a proprietary antiseptic solution from its high-margin infection-control portfolio, across leading public and private hospital groups in Greece. C-Sept PRO has generated average monthly sales exceeding $93,000 over the past six months, accelerating to more than $108,000 per month over the past three months.

globenewswire.com - 2026-06-24 15:37:00

CHICAGO, June 23, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has signed an agreement to deploy an Artificial Intelligence (AI)-powered call center to support customer communications, including order intake and routine support functions, marking the latest step in the Company's ongoing integration of AI across its operations.

globenewswire.com - 2026-06-23 15:35:00

CHICAGO, June 22, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided a consolidated summary of the contract manufacturing orderbook secured through its wholly owned subsidiary, Cana Laboratories S.A. (“Cana”).

globenewswire.com - 2026-06-22 10:30:00

CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, CosmoFarm S.A. (“CosmoFarm”), delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized run-rate of over $60 million.

globenewswire.com - 2026-06-18 15:34:00

CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced its entry into the global beauty and personal care market. Sales of a new skincare brand — a premium, Korean-developed collagen-based skincare line — have already commenced in the United States and have been live for over a month.

globenewswire.com - 2026-06-17 15:35:00

CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that, through its wholly owned subsidiary Cana Laboratories S.A. ("Cana"), it has entered into a five-year contract manufacturing agreement with Pharmex S.A.

globenewswire.com - 2026-06-17 09:27:00

CHICAGO, June 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided an update on its United States market entry through the "18 Series," a science-driven nutraceutical platform built on proprietary ingredients, published clinical research, and exact clinical dosing, and disclosed projected annualized revenue and implied gross profit for four of its launched products. Since launching the 18 Series in the U.S., Cosmos Health has introduced five products: Noor18™, Liv18™, Cur18™, Fort18™, and Oliv18™ — four of which currently have disclosed projections.

globenewswire.com - 2026-06-15 09:00:00

CHICAGO, June 12, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has received new contract manufacturing orders from Nassington and Verisfield for a combined 253,657 units across a range of medicines and other pharmaceutical products. Under the orders, Cana will manufacture Gritse oral solution 0.4 mg/ml (bottle x 150 ml); Gritse forte oral solution 2 mg/ml (bottle x 50 ml); Gritse forte oral solution 4 mg/ml (bottle x 50 ml); Fungofort cutaneous spray, solution (30 ml); Paco-4 tablets (250+250+65+35 mg); dexamethasone 2 mg/5 ml, in 50 ml and 150 ml bottle and oral solution presentations; and Foproct rectal cream (1 + 1.5%).

globenewswire.com - 2026-06-12 15:33:00

Strong sales momentum: across the UK and Greece, the brands' first two markets. Over $1.5 million in sales: C-Scrub and C-Sept have generated over $1.5 million in combined annualized sales across the United Kingdom and Greece.

globenewswire.com - 2026-06-12 09:29:00

Doc Pharma financial profile: approximately $24 million asset base, approximately $6.7 million in average annual revenue and approximately $3.2 million in average annual gross profit. Immediately accretive: expected to support margin expansion, profitability, and cash flow.

globenewswire.com - 2026-06-11 15:31:00

Extension granted through December 7, 2026 Reflects the Company's compliance with all other applicable Nasdaq listing requirements. Cosmos Health does not intend to effect a reverse stock split unless necessary to maintain its Nasdaq listing. CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that it has been granted an additional 180-day period to regain compliance with the Nasdaq minimum bid price requirement.

globenewswire.com - 2026-06-11 09:35:00

CHICAGO, June 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has secured a three-year contract manufacturing agreement with Verisfield S.A. (“Verisfield”), a specialty pharmaceutical company focused on the development and marketing of generic and differentiated pharmaceutical products across multiple therapeutic categories.

globenewswire.com - 2026-06-10 15:32:00

Key Highlights Record revenue, continued momentum: all-time high $65.3M in FY2025; strongest-ever Q1 2026, carrying into Q2. Record operational momentum: CosmoFarm wholesale distribution and GMP-certified Cana contract manufacturing both delivering record volumes.

globenewswire.com - 2026-06-10 09:00:00

CHICAGO, June 09, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has inaugurated a new, state-of-the-art capsule production line and secured an additional contract manufacturing agreement with Provident Pharmaceuticals ("Provident"), a specialty pharmaceutical company focused on the commercialization and marketing of niche and legacy pharmaceutical products and medical devices in specific therapeutic areas. Under the new five-year agreement, Cana will manufacture 385,000 units of CERTORUN® (sertraline hydrochloride) over the five-year period, at an annual production volume of 77,000 units.

globenewswire.com - 2026-06-09 15:30:00

KEY HIGHLIGHTS Cana Laboratories, Cosmos Health's wholly owned subsidiary, acquires international patent application WO2025108566A1 from Cloudpharm P.C. Patent protection being pursued at national and regional levels across key international markets Technology supports next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare product development Expands nanotechnology investment initiatives, leveraging Cana Laboratories' European GMP-certified manufacturing capabilities Aligned with the Company's broader strategy of expanding its IP portfolio, strengthening vertical integration, and driving long-term shareholder value CHICAGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A.

globenewswire.com - 2026-06-08 10:00:00

Oliv18™ expands the 18 Series with a USDA and EU organic certified, 100% solvent-free, whole olive polyphenol formulation from the Moroccan Saharan desert Hydroxytyrosol — the key active in Oliv18™ — is the highest ORAC polyphenol A single 250 mg daily dose meets EFSA's 5 mg/day hydroxytyrosol minimum dose for protection against LDL oxidation A single daily dose equivalent to approximately 11 teaspoons of good quality extra virgin olive oil — compared to an average of half a teaspoon per day in the U.S. Targeting the multibillion cardiovascular health and antioxidant markets, initially in the United States and globally thereafter — within a combined global market landscape projected to exceed $33 billion by 2035 CHICAGO, June 05, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the U.S. launch of Oliv18™, further expanding its science-driven 18 Series nutraceutical platform into cardiovascular and antioxidant categories. Scientific Background Oliv18™ is formulated with a whole olive polyphenol extract derived from the fruit and leaf of olive trees cultivated in the Moroccan stretch of the Saharan Desert.

globenewswire.com - 2026-06-05 09:25:00

CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its proprietary brand, Sky Premium Life, is now available for shipment across all 27 European Union Member States through Skroutz, significantly expanding the brand's international reach. A total of 96 Sky Premium Life products are now accessible to consumers across all 27 European Union Member States through Skroutz, with shipments reaching key markets across Western Europe, Northern Europe, and Central and Eastern Europe.

globenewswire.com - 2026-06-04 15:57:00

Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 million Proceeds could fund a meaningful acquisition or eliminate debt entirely Company remains fully committed to its core healthcare operations CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced it is exploring the monetization of non-core assets, having identified approximately $20 million in assets that can be converted to liquidity without impacting the Company's operational capabilities. The Company is fully committed to its core healthcare operations and views these assets as non-core in the sense that they can be monetized to strengthen the balance sheet, fund strategic initiatives, and close the gap between intrinsic value and current market valuation.

globenewswire.com - 2026-06-04 09:25:00

Cosmos Holdings Inc. (NASDAQ:COSM)(dba Cosmos Health) is entering the animal health market, extending its C-Scrub brand into the veterinary space after the product passed testing against European standards, the company said Monday. The move takes C-Scrub, one of the company's branded products, into veterinary applications following what Cosmos described as successful European standard testing.

proactiveinvestors.com - 2026-06-01 12:18:22

CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the extension of its C-Scrub antimicrobial wash brand into the veterinary and animal health sector through the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the Company's first entry into the animal health market. The Company intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion to follow.

globenewswire.com - 2026-06-01 08:25:00

Revenue increasing 207% at a 32% CAGR: From $65.3 million in 2025 to $200.6 million by 2029, driven by strong growth across all core segments Gross profit growing 801% to $71.2M: Margins expanding from 12.1% to 35.5% — driven by a structural shift toward high-margin proprietary segments Net income improving by $50.1M: Transition to profitability in 2027; net income of $31.0 million by 2029 Self-funding growth model: Operating cash flow turning positive in 2027 at $11.9 million, more than doubling to $24.0 million by 2029 Balance sheet transformation: Cash up 18-fold to $62.9 million; all convertible notes repaid; cash anticipated to exceed total debt levels by 2027 Shareholder value: stockholders' equity up 402% to $92.3 million and per-share value creation with EPS of $0.73 by 2029 Clear growth drivers: High-margin proprietary products, expansion of the distribution and manufacturing platform, global partnerships, advancement of the R&D pipeline, AI-driven efficiencies, and disciplined capital allocation — with the U.S. serving as a new growth engine alongside selective M&A activity CHICAGO, May 26, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced its financial guidance for the 2026–2029 period. Cosmos Health enters this guidance period following its strongest financial performance in Company history — full year 2025 revenue of $65.3 million, up 20% year-over-year, with gross profit increasing 83%, gross margin expanding 418 basis points, and cash rising more than tenfold to $3.5 million.

globenewswire.com - 2026-05-26 09:34:00

No dilution to existing shareholders Reduction in total outstanding warrant overhang Simplifies capital structure CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its Series B warrants expired unexercised in accordance with their original terms at 5:00 p.m. New York City time on May 19, 2026.

accessnewswire.com - 2026-05-21 14:20:00

Record Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segments Total liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in convertible note and credit facility balances Stockholders' equity increased by $1.4M, or 7.6%, with the liabilities-to-assets ratio improving by 370 basis points Adjusted EBITDA near breakeven as increased revenue was offset by strategic investments to support global growth Record momentum continues into Q2 2026 with U.S. expansion actively underway CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Income Statement Cosmos Health delivered the highest Q1 revenue in Company history with continued progress toward adjusted profitability, reflecting broad-based commercial strength - over 75 new pharmacies added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories.

accessnewswire.com - 2026-05-21 09:15:00

Advisory Agreement Secured: To advance the Company's EIB-backed R&D financing program €25 million potential financing opportunity: Up to 50% of the Company's €50 million planned R&D program Institutional-grade capital: Potential long-term, attractively structured financing from the EU's premier development bank R&D acceleration: Strengthens and expands the Company's development pipeline across its portfolio Value creation catalyst: Landmark funding opportunity supporting long-term innovation and growth CHICAGO, IL / ACCESS Newswire / May 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that, through its wholly owned subsidiary Cana Laboratories, it is pursuing a strategic research and development (R&D) financing program with the European Investment Bank (EIB), the financing arm of the European Union and one of the world's largest multilateral lenders. In connection with this initiative, Cana Laboratories has entered into an advisory agreement with the EIB to support the Company's progress under the EIB-backed financing program.

accessnewswire.com - 2026-05-14 09:00:00

CHICAGO, IL / ACCESS Newswire / May 12, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has filed with the U.S. Securities and Exchange Commission (the "SEC") a request for withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-283910), originally filed on December 18, 2024 and last amended on June 3, 2025 (the "Registration Statement"), as the Company no longer intends to pursue a public offering under the Registration Statement at this time.

accessnewswire.com - 2026-05-12 10:15:00

CHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced it is projecting Fort18™ to generate over $3.2 million in incremental annual U.S. revenue within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions. Fort18™ is the latest addition to the Company's "18 Series," a growing portfolio of science-based nutraceutical products.

accessnewswire.com - 2026-05-11 14:25:00

2026 revenue forecast raised: Zacks increases 2026 revenue estimate to $103.2 million, up from $98.6 million in its prior January 2026 report EPS outlook upgraded: Zacks now expects Cosmos Health to cross into positive EPS territory in 2026 $4.50 valuation reaffirmed: Updated report maintains valuation target, citing improving fundamentals and operational momentum Long-term growth trajectory maintained: Zacks continues to project revenue of approximately $130.8 million in 2027 "Clear inflection point": Zacks highlights Cosmos Health's accelerating operational momentum and strategic evolution into a higher-margin healthcare platform with multiple growth vectors CHICAGO, IL / ACCESS Newswire / May 8, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that Zacks Small-Cap Research has published an updated research report raising its 2026 revenue and EPS forecasts, while reaffirming its $4.50 per share valuation. The updated report projects revenue growth from a record $65.3 million in fiscal year 2025 to $103.2 million in 2026 - up from Zacks' prior forecast of $98.6 million issued in January 2026 - with further expansion to approximately $130.8 million in 2027.

accessnewswire.com - 2026-05-08 11:25:00

CHICAGO, IL / ACCESS Newswire / April 30, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it is projecting Cur18™ to generate over $2.5 million in incremental annual revenue in the United States within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions. Cur18™ is part of the Company's recently introduced "18 Series," a portfolio of science-based nutraceutical products.

accessnewswire.com - 2026-04-30 12:50:00

Science-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in clinical trials; a bar the vast majority of the supplement industry cannot meet Three products introduced, $7.8 billion addressable market: Noor18™, Liv18™, and Cur18™ - targeting healthy aging & beauty, liver & metabolic support, and inflammation & mobility across three of the fastest-growing health categories in the U.S. Institutional-grade scientific standard: Patented ingredients, published randomized controlled trials, exact clinical dosing - built to the standard of institutional science, not marketing Compounding platform value, 18 clinically validated products targeted: Each new "18" product retroactively strengthens every existing one - the portfolio becomes more valuable with every addition CHICAGO, IL / ACCESS Newswire / April 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the U.S. introduction of the "18 Series" - a premium nutraceutical platform designed to meet growing consumer demand for clinically validated health solutions. 1. The 18 Series - Overview Cosmos Health Inc. is executing a disciplined, science-first strategy to build the what we believe to be most credible clinical supplement portfolio in the United States.

accessnewswire.com - 2026-04-21 12:50:00

Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of schedule Production commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturing - mitigating tariff risk $5M+ projected annual revenue: Liv18™ expected to generate over $5 million annually at approximately 75% gross margins Direct-to-consumer model: scalable DTC strategy with targeted advertising and disciplined capital allocation Early U.S. traction confirmed: commercial indicators from existing products shaping revenue expectations and go-to-market strategy CHICAGO, IL / ACCESS Newswire / April 20, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided a commercial and financial update on Liv18™, its clinically validated liver health supplement, as the Company accelerates its expansion across the United States. The Company has successfully completed Phase 1 execution for Liv18™ (defined as product development, packaging, and initial commercial setup) ahead of schedule.

accessnewswire.com - 2026-04-20 10:55:00

Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts. Derived predominantly from turmeric (~98.5%), maintaining a composition closer to the natural profile of the plant.

accessnewswire.com - 2026-04-17 14:00:00